Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
May 02 2019 - 8:00AM
Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company
focused on developing, manufacturing and commercializing innovative
extended-release (XR) products using its proprietary
modified-release drug delivery and orally disintegrating tablet
(ODT) technology platforms, today announced that it will report its
first quarter 2019 financial results prior to the opening of U.S.
financial markets on Thursday, May 9, 2019. Neos management will
host a conference call and live audio webcast to discuss these
results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877)
388-8985 for domestic calls, or +1 (562) 912-2654 for international
callers, and referencing conference ID number 5799342. A live audio
webcast for the conference call will be available on the Investor
Relations page of the company’s website at
http://investors.neostx.com/ and will be available for replay
following the call for 30 days.
About Neos TherapeuticsNeos
Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company
focused on developing, manufacturing and commercializing products
utilizing its proprietary modified-release drug delivery technology
platforms. Adzenys XR-ODT® (amphetamine) extended-release orally
disintegrating tablets (see Full Prescribing Information, including
Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release
orally disintegrating tablets (see Full Prescribing Information,
including Boxed WARNING), and Adzenys-ER® (amphetamine)
extended-release oral suspension (see Full Prescribing Information,
including Boxed WARNING), all for the treatment of ADHD, are three
approved products using the Company’s extended-release technology
platform. Additional information about Neos is available at
www.neostx.com.
CONTACTS:
Richard I. EisenstadtChief Financial OfficerNeos
Therapeutics(972) 408-1389reisenstadt@neostx.com
Sarah McCabe Investor Relations Stern Investor
Relations, Inc. (212) 362-1200 sarah.mccabe@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024